Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis. American journal of hematology Gong, C. L., Studdert, A. L., Liedtke, M. 2018
View details for PubMedID 30536952